FIR: Efficacy, Safety, and Biomarker Analysis of a Phase II Open-Label Study of Atezolizumab in PD-L1–Selected Patients With NSCLC

Journal of Thoracic Oncology - United States
doi 10.1016/j.jtho.2018.05.004

Related search